Subscribe to our Newsletters !!
The safety and quality of produced medicines is ex
In the analytical lab space, safety and accuracy a
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
2026 marks a new chapter for the pharmaceutical an
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
The vaccine candidate, which has been licensed to AstraZeneca, has published interim late stage trial results showing higher efficacy when a half dose is followed by a complete dose, in contrast to a two full-dose regime, though more work needs to be done to affirm the outcome.
The details from the Phase I/II clinical trials released on December 17 made no reference to the half-dose/full-dose regime, which Oxford has said had been”unplanned” but accepted by regulators.
The university said it had explored two dosing regimes in early stage trials, a full-dose/full-dose regime and a full-dose/half-dose regime, investigated as a possible”dose sparing” strategy.
“The booster doses of the vaccine are both shown to induce stronger antibody responses than one dose, the conventional dose/standard dose inducing the ideal response,” the university said in a statement.
